GlassScriptPhysician profile
Samer Kottiech
NPI 1447221288
$9,123.30
in general payments reported to CMS, 2019-2025
32 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,771 · 2020: $456 · 2021: $800 · 2022: $763 · 2023: $1,230 · 2024: $1,311 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,333.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,740.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $911.23 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $891.21 | 2019-2025 | |
| Amgen INC. | $708.39 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.41 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $613.87 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $460.90 | 2021-2025 | Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $436.29 | 2022-2025 | |
| Heartflow, INC. | $419.06 | 2023-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $315.78 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $289.22 | 2021-2025 | Verquvo |
| Pfizer INC. | $237.55 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $214.55 | 2025 | Amvuttra |
| Corcept Therapeutics | $202.21 | 2023-2024 | Korlym |
| Alexion Pharmaceuticals, INC. | $196.77 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $136.07 | 2019 | |
| Esperion Therapeutics, INC. | $129.00 | 2021-2023 | Nexletol |
| Scpharmaceuticals INC. | $72.91 | 2023-2025 | |
| Amarin Pharma, INC. | $70.50 | 2019-2021 | |
| Gilead Sciences, INC. | $60.00 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $46.64 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $41.55 | 2024 | Arcalyst |
| Boston Scientific Corporation | $41.00 | 2024 | Watchman Flx |
| Abbott Laboratories | $39.11 | 2020-2021 | |
| Intra-Sana Laboratories | $35.00 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Regeneron Healthcare Solutions, INC. | $29.71 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $28.83 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $26.72 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $24.01 | 2025 | Assure Wcd |
| Bardy Diagnostics, INC. | $22.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.88 | 2019 | |
| Abbvie INC. | $17.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Kottiech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.